July 09th, 2023

On Wednesday, July 12, several companies are expected to report their financial results, including: MillerKnoll, Inc. (Nasdaq: MLKN), a consumer goods company, is set to release its financial results for the fourth quarter and full-year fiscal 202. Read more

July 09th, 2023

Several companies are expected to report their financial results on Monday, July 10, including: Helen of Troy Limited (Nasdaq: HELE), a company operating in the consumer products industry, is set to release its first-quarter fiscal 2024 results be. Read more

July 07th, 2023

FOR IMMEDIATE RELEASE 2023-127 Washington D.C. / CRWE PRESS RELEASE / July 7, 2023 - The Securities and Exchange Commission today charged former U.S. Army financial counselor Caz L. Craffy for defrauding Gold Star family members and others b. Read more

July 07th, 2023

AZZ Inc. (NYSE: AZZ) reported first-quarter fiscal 2024 earnings per share (EPS) of $1.14 and sales of $390.87 million, slightly below the consensus EPS of $1.16 on revenue of $396.65 million. Despite the earnings results, the company is. Read more

July 07th, 2023

Shares of ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) surged over 20% in early trade after the European Patent Office granted a patent (number EP 2 836 221) for its Cholesterol Efflux Mediator VAR 200 in the treatment of diabetic nephropathy/diabetic k. Read more

July 07th, 2023

Ford Motor Company (NYSE: F), a renowned automobile manufacturer, was maintained with an Overweight rating by Morgan Stanley, who raised the price target from $14 to $16. Based on Thursday's closing price of $14.98, the adjusted price target indic. Read more

July 07th, 2023

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more

July 07th, 2023

Lockheed Martin Corporation (NYSE: LMT) has secured two significant contracts with a combined value of $136,102,558. The first contract is a $122,706,700 cost-plus-fixed-fee modification to an existing contract. This modification focuses on critic. Read more

July 06th, 2023

Shares of Cronos Group Inc. (Nasdaq: CRON) experienced a surge of over 5% in the extended session after confirming receipt of several unsolicited indications of interest from third parties, signaling potential transactions involving Cronos and these . Read more

July 06th, 2023

Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 -   Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more